Logo image of PULM

PULMATRIX INC (PULM) Stock Fundamental Analysis

NASDAQ:PULM - Nasdaq - US74584P3010 - Common Stock - Currency: USD

8.92  -0.09 (-1%)

After market: 9.36 +0.44 (+4.93%)

Fundamental Rating

4

PULM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for PULM as it has an excellent financial health rating, but there are worries on the profitability. PULM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PULM has reported negative net income.
In the past year PULM has reported a negative cash flow from operations.
PULM had negative earnings in each of the past 5 years.
In the past 5 years PULM reported 4 times negative operating cash flow.
PULM Yearly Net Income VS EBIT VS OCF VS FCFPULM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -83.89%, PULM is doing worse than 74.59% of the companies in the same industry.
PULM has a Return On Equity (-88.42%) which is in line with its industry peers.
Industry RankSector Rank
ROA -83.89%
ROE -88.42%
ROIC N/A
ROA(3y)-42.44%
ROA(5y)-47.01%
ROE(3y)-62.76%
ROE(5y)-91.73%
ROIC(3y)N/A
ROIC(5y)N/A
PULM Yearly ROA, ROE, ROICPULM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

PULM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PULM Yearly Profit, Operating, Gross MarginsPULM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PULM has been increased compared to 1 year ago.
PULM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PULM Yearly Shares OutstandingPULM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
PULM Yearly Total Debt VS Total AssetsPULM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

PULM has an Altman-Z score of -2.92. This is a bad value and indicates that PULM is not financially healthy and even has some risk of bankruptcy.
PULM has a Altman-Z score of -2.92. This is comparable to the rest of the industry: PULM outperforms 40.54% of its industry peers.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.92
ROIC/WACCN/A
WACC9.77%
PULM Yearly LT Debt VS Equity VS FCFPULM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

A Current Ratio of 19.40 indicates that PULM has no problem at all paying its short term obligations.
PULM has a Current ratio of 19.40. This is amongst the best in the industry. PULM outperforms 92.97% of its industry peers.
PULM has a Quick Ratio of 19.40. This indicates that PULM is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PULM (19.40) is better than 92.97% of its industry peers.
Industry RankSector Rank
Current Ratio 19.4
Quick Ratio 19.4
PULM Yearly Current Assets VS Current LiabilitesPULM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

PULM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.30%, which is quite impressive.
Looking at the last year, PULM shows a very strong growth in Revenue. The Revenue has grown by 47.13%.
Measured over the past years, PULM shows a very strong growth in Revenue. The Revenue has been growing by 117.48% on average per year.
EPS 1Y (TTM)29.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.07%
Revenue 1Y (TTM)47.13%
Revenue growth 3Y-16.71%
Revenue growth 5Y117.48%
Sales Q2Q%-78.89%

3.2 Future

The Earnings Per Share is expected to grow by 22.73% on average over the next years. This is a very strong growth
PULM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.85% yearly.
EPS Next Y-18.91%
EPS Next 2Y-14.37%
EPS Next 3Y12.08%
EPS Next 5Y22.73%
Revenue Next Year1%
Revenue Next 2Y1%
Revenue Next 3Y33.81%
Revenue Next 5Y40.85%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PULM Yearly Revenue VS EstimatesPULM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PULM Yearly EPS VS EstimatesPULM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PULM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PULM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PULM Price Earnings VS Forward Price EarningsPULM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PULM Per share dataPULM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PULM's earnings are expected to grow with 12.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.37%
EPS Next 3Y12.08%

More info and screens

0

5. Dividend

5.1 Amount

PULM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULMATRIX INC

NASDAQ:PULM (2/21/2025, 8:00:01 PM)

After market: 9.36 +0.44 (+4.93%)

8.92

-0.09 (-1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)03-26 2025-03-26/bmo
Inst Owners9.28%
Inst Owner Change-98.96%
Ins Owners0.65%
Ins Owner Change0%
Market Cap32.56M
Analysts82.86
Price Target10.2 (14.35%)
Short Float %1.45%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.25
P/FCF N/A
P/OCF N/A
P/B 2.98
P/tB 2.98
EV/EBITDA N/A
EPS(TTM)-3.86
EYN/A
EPS(NY)-5.05
Fwd EYN/A
FCF(TTM)-3.34
FCFYN/A
OCF(TTM)-3.14
OCFYN/A
SpS2.74
BVpS2.99
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.89%
ROE -88.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.44%
ROA(5y)-47.01%
ROE(3y)-62.76%
ROE(5y)-91.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 502.86%
Cap/Sales 7.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.4
Quick Ratio 19.4
Altman-Z -2.92
F-Score4
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)214.36%
Cap/Depr(5y)160.74%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.07%
EPS Next Y-18.91%
EPS Next 2Y-14.37%
EPS Next 3Y12.08%
EPS Next 5Y22.73%
Revenue 1Y (TTM)47.13%
Revenue growth 3Y-16.71%
Revenue growth 5Y117.48%
Sales Q2Q%-78.89%
Revenue Next Year1%
Revenue Next 2Y1%
Revenue Next 3Y33.81%
Revenue Next 5Y40.85%
EBIT growth 1Y55.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.7%
OCF growth 3YN/A
OCF growth 5YN/A